JP2007512347A - 緑内障を予防するかまたは治療する方法 - Google Patents

緑内障を予防するかまたは治療する方法 Download PDF

Info

Publication number
JP2007512347A
JP2007512347A JP2006541438A JP2006541438A JP2007512347A JP 2007512347 A JP2007512347 A JP 2007512347A JP 2006541438 A JP2006541438 A JP 2006541438A JP 2006541438 A JP2006541438 A JP 2006541438A JP 2007512347 A JP2007512347 A JP 2007512347A
Authority
JP
Japan
Prior art keywords
compound
glaucoma
statin
coa
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006541438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512347A5 (https=
Inventor
エプスタイン，デービッド・エル
リー，ポール・ピー
ラオ，ヴァサンス
Original Assignee
デューク・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デューク・ユニバーシティー filed Critical デューク・ユニバーシティー
Publication of JP2007512347A publication Critical patent/JP2007512347A/ja
Publication of JP2007512347A5 publication Critical patent/JP2007512347A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006541438A 2003-11-26 2004-11-26 緑内障を予防するかまたは治療する方法 Pending JP2007512347A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52491203P 2003-11-26 2003-11-26
PCT/US2004/039657 WO2005053683A1 (en) 2003-11-26 2004-11-26 A method of preventing or treating glaucoma

Publications (2)

Publication Number Publication Date
JP2007512347A true JP2007512347A (ja) 2007-05-17
JP2007512347A5 JP2007512347A5 (https=) 2008-01-17

Family

ID=34652282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541438A Pending JP2007512347A (ja) 2003-11-26 2004-11-26 緑内障を予防するかまたは治療する方法

Country Status (4)

Country Link
US (1) US8415364B2 (https=)
EP (1) EP1722780A4 (https=)
JP (1) JP2007512347A (https=)
WO (1) WO2005053683A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007534699A (ja) * 2004-04-26 2007-11-29 アルコン，インコーポレイティド 高眼圧症及び緑内障の治療ためのスタチン
JP2011518828A (ja) * 2008-04-26 2011-06-30 アルコン リサーチ， リミテッド 眼球障害の処置のためのｐａｉ−１の発現および活性インヒビター

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
EP1812017A2 (en) * 2004-10-21 2007-08-01 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US9597289B2 (en) 2006-04-26 2017-03-21 Rosemont Pharmaceuticals Ltd. Liquid oral simvastatin compositions
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10493274B2 (en) 2013-12-09 2019-12-03 Purdue Research Foundation Optical pressure treatment through electrical stimulation
AU2018312121B2 (en) 2017-08-04 2023-12-21 Purdue Research Foundation Multi-coil wireless power transfer assembly for wireless glaucoma therapy
US11191962B2 (en) 2018-03-12 2021-12-07 Purdue Research Foundation Stimulus coil and pulse generator for wireless glaucoma therapy
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2025080770A1 (en) * 2023-10-10 2025-04-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Ocular applications of combination therapy using statins and matrix bound vesicles (mbvs)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0334934A (ja) * 1989-06-05 1991-02-14 Sanofi Sa 眼病治療におけるスタチン誘導体の使用
JPH07188284A (ja) * 1993-12-28 1995-07-25 Ito Ham Kk 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤
WO2000009162A1 (en) * 1998-08-17 2000-02-24 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
JP2000336042A (ja) * 1999-03-25 2000-12-05 Santen Pharmaceut Co Ltd 眼圧下降剤
WO2001054728A1 (fr) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOUVEAUX REMEDES ET UTILISATION D'UN AGONISTE β3
WO2002067901A1 (en) * 2001-02-22 2002-09-06 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
WO2003051822A1 (en) * 2001-12-19 2003-06-26 Astrazeneca Ab Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
JP2003180399A (ja) * 2001-09-28 2003-07-02 Pfizer Prod Inc アルドースレダクターゼ遺伝子上流のａ−ｃ反復ｚ配列に関する方法
WO2003077910A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
WO2003080070A2 (en) * 2002-03-22 2003-10-02 Novartis Ag Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
JP2003292442A (ja) * 2002-01-29 2003-10-15 Santen Pharmaceut Co Ltd ブナゾシンとプロスタグランジン類からなる緑内障治療剤

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (https=) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US5041450A (en) * 1988-06-29 1991-08-20 Research Corporation Technologies, Inc. Treatment of ocular inflammation
JP2853227B2 (ja) 1988-10-13 1999-02-03 ノバルテイス・アクチエンゲゼルシヤフト ７置換‐ヘプト‐６‐エン酸、ヘプタン酸及び誘導体並びにそれらの中間体の製法
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
ATE179074T1 (de) * 1991-11-07 1999-05-15 Univ Southern California Zusammensetzungen und verfahren zur verhinderung der adhäsionbildung
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5811515A (en) * 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
ATE308981T1 (de) 1995-08-14 2005-11-15 Scripps Research Inst Verfahren und mittel zur hemmung der durch alpha v beta 5 vermittelten angiogenese
JPH1017488A (ja) 1996-06-25 1998-01-20 Asahi Glass Co Ltd 緑内障治療薬
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
SE0002354D0 (sv) 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
US20030195167A1 (en) 2002-04-15 2003-10-16 Kowa Co., Ltd. PTX3-gene expression inhibitor
JP2004149480A (ja) 2002-10-31 2004-05-27 Saisentan Igaku Kenkyusho:Kk 経口又は経皮投与用の眼科疾患治療剤
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
ATE404189T1 (de) * 2004-04-26 2008-08-15 Alcon Inc Statine zur behandlung von okularer hypertonie und glaukom
WO2005105155A1 (en) 2004-04-28 2005-11-10 Saitama Medical School Methods for delivering a gene product to the eye

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0334934A (ja) * 1989-06-05 1991-02-14 Sanofi Sa 眼病治療におけるスタチン誘導体の使用
JPH07188284A (ja) * 1993-12-28 1995-07-25 Ito Ham Kk 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤
WO2000009162A1 (en) * 1998-08-17 2000-02-24 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
JP2000336042A (ja) * 1999-03-25 2000-12-05 Santen Pharmaceut Co Ltd 眼圧下降剤
WO2001054728A1 (fr) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOUVEAUX REMEDES ET UTILISATION D'UN AGONISTE β3
WO2002067901A1 (en) * 2001-02-22 2002-09-06 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
JP2003180399A (ja) * 2001-09-28 2003-07-02 Pfizer Prod Inc アルドースレダクターゼ遺伝子上流のａ−ｃ反復ｚ配列に関する方法
WO2003051822A1 (en) * 2001-12-19 2003-06-26 Astrazeneca Ab Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
JP2003292442A (ja) * 2002-01-29 2003-10-15 Santen Pharmaceut Co Ltd ブナゾシンとプロスタグランジン類からなる緑内障治療剤
WO2003077910A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
WO2003080070A2 (en) * 2002-03-22 2003-10-02 Novartis Ag Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007534699A (ja) * 2004-04-26 2007-11-29 アルコン，インコーポレイティド 高眼圧症及び緑内障の治療ためのスタチン
JP2011518828A (ja) * 2008-04-26 2011-06-30 アルコン リサーチ， リミテッド 眼球障害の処置のためのｐａｉ−１の発現および活性インヒビター

Also Published As

Publication number Publication date
US20070161699A1 (en) 2007-07-12
EP1722780A4 (en) 2008-12-17
WO2005053683A1 (en) 2005-06-16
EP1722780A1 (en) 2006-11-22
US8415364B2 (en) 2013-04-09

Similar Documents

Publication Publication Date Title
JP2007512347A (ja) 緑内障を予防するかまたは治療する方法
US6274603B1 (en) Methods for increasing ApoE levels for the treatment of neurodegenerative disease
US10426790B2 (en) Treatment of allergic eye conditions with cyclodextrins
Zamrini et al. Association between statin use and Alzheimer’s disease
Zhou et al. Prevention and treatment of dementia or Alzheimer’s disease by statins: a meta-analysis
Endo et al. Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes
JP2010189432A (ja) 脳の代謝機能不全のための栄養補充剤
Kawahara et al. Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins
CN113413387A (zh) 治疗炎症或神经性疼痛的方法
CN109908140A (zh) 生物素治疗多发性硬化的用途
WO2022150580A1 (en) Treatment of dry eye disease
AU2025203339A1 (en) Therapeutic Uses of Tirzepatide
AU2012271068A1 (en) Scyllo-inositol for the treatment of behavioral and psychiatric disorders
Sano Noncholinergic treatment options for Alzheimer's disease
EP2600862A2 (en) Inhibitors of erk for developmental disorders of neuronal connectivity
Chue The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective
CN1230173C (zh) 糖尿病合并症预防及治疗剂
Giri et al. Combinatorial therapy in Alzheimer's disease
Wong et al. Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study
Nunes et al. IMPACT OF CENTER-INVOLVED DIABETIC MACULAR EDEMA ON VISION-RELATED QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES: A CROSS-SECTIONAL STUDY
ES2605025T3 (es) Uso de fenofibrato o un derivado del mismo para tratar retinopatía diabética
Hwang et al. Preventive Effect of Diospyros kaki on Intraocular Pressure and Dry Eye: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Jagarlamudi et al. A simple randomized comparative study to evaluate the efficacy of 0.7% w/v Olopatadine hydrochloride ophthalmic solution and the Fixed Dose Combination of 0.1% w/v Olopatadine hydrochloride and 0.4% w/v Ketorolac tromethamine ophthalmic solution for the
EA051835B1 (ru) Терапевтическое применение тирзепатида
Zagaria Special considerations for lowering lipids in seniors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110228

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110316

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110824

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110824

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110831

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110922

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111216